Precision biologics for oncology and rare diseases
We engineer multivalent, multispecific therapeutics using our proprietary single-domain antibody platform — designed to act precisely within the tumor microenvironment.
Core Technology
The sdAb platform: precision at the molecular level
Our single-domain antibody (sdAb) platform enables the creation of multivalent and multispecific biologics — molecules engineered to engage multiple targets simultaneously with exceptional precision. Unlike conventional antibodies, sdAbs are smaller, more stable, and uniquely suited to penetrate the complex architecture of the tumor microenvironment.
Research Pipeline
Programs advancing across oncology and rare disease
Our Story
Born from a landmark deal. Built for what comes next.
Inhibrx Biosciences was established in January 2024 following the sale of INBRX-101 to Sanofi — a transaction that validated our platform and funded our future. Headquartered in La Jolla, California, we are a focused team of scientists and drug developers committed to translating the biology of the tumor microenvironment into medicines that matter.
Advancing the science of targeted biologics
Explore our pipeline programs and the platform technology that makes them possible.